CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease-Reference-Cited by-同舟云学术

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

Published:2017-11-01 Issue:59 Volume:8 Page:100421-100432
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kosovec Juliann E.¹,Zaidi Ali H.¹,Omstead Ashten N.¹,Matsui Daisuke²,Biedka Mark J.¹,Cox Erin J.¹,Campbell Patrick T.¹,Biederman Robert W.W.³,Kelly Ronan J.⁴,Jobe Blair A.¹

Affiliation:

1. Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA

2. Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

3. McGinnis Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA

4. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of abemaciclib and curcumin administration on sex hormones, reproductive functions, and oxidative DNA expression in rats;Biotechnic & Histochemistry;2024-08-21

2. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects;Molecular Pharmaceutics;2024-06-18

3. Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma;Nature Communications;2023-07-15

4. Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation;Frontiers in Pharmacology;2023-05-10

5. CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas;Molecular Carcinogenesis;2023-05-03